{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:10:35Z","timestamp":1774260635153,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The increasing number of dialysis patients presents a significant public health challenge in Japan. While the number of patients initiating dialysis due to chronic glomerulonephritis (CGN) or diabetic kidney disease (DKD) has decreased, the incidence of dialysis initiation attributed to nephrosclerosis has gradually increased. To investigate regional differences, Hokkaido, Japan, was selected as one regional example in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were extracted from a web-based national database for patients aged\u2009\u2265\u200940\u00a0years who initiated dialysis between 2012 and 2021. Patients were categorized according to sex, age, and underlying disease. Dialysis initiation rates were calculated as the number of new dialysis patients divided by the corresponding population. To assess temporal changes, the 2021\/2016 ratio was calculated by dividing the initiation rate in 2021 by that in 2016 for each prefecture.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In Hokkaido, the dialysis initiation rates for DKD declined across all age groups, whereas the national rate increased in men aged\u2009\u2265\u200980\u00a0years. For nephrosclerosis, the initiation rates rose among older adults both nationally and in Hokkaido, although the increase in Hokkaido was more gradual. CGN-related rates decreased consistently across all age groups, both nationally and in Hokkaido. Prefectures with 2021\/2016 ratio of\u2009\u2265\u20091 were more frequently observed among patients with nephrosclerosis than among those with CGN or DKD, especially among older populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dialysis initiation rates in Hokkaido decreased in most subgroups compared with national trends. Given the rising incidence of nephrosclerosis among older adults, targeted interventions at the prefectural level are urgently warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-026-02831-y","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:50:25Z","timestamp":1772110225000},"page":"670-678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent trends in dialysis initiation in Japan: a region\u2011specific descriptive analysis using Hokkaido as an example"],"prefix":"10.1007","volume":"30","author":[{"given":"Hirofumi","family":"Sakuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeko","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reina","family":"Suetsugu-Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoki","family":"Matsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5398-3667","authenticated-orcid":false,"given":"Naoki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"2831_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s41100-023-00478-z","volume":"9","author":"N Hanafusa","year":"2023","unstructured":"Hanafusa N, Abe M, Joki N, Ogawa T, Kanda E, Kikuchi K, et al. Annual dialysis data report 2019, JSDT renal data registry. Renal Replace Therapy. 2023;9:47.","journal-title":"Renal Replace Therapy."},{"key":"2831_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.34067\/KID.0000162020","volume":"1","author":"N Hanafusa","year":"2020","unstructured":"Hanafusa N, Fukagawa M. Global dialysis perspective: Japan. Kidney360. 2020;1:416\u20139.","journal-title":"Kidney360"},{"key":"2831_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/1744-9987.12314","volume":"19","author":"T Takura","year":"2015","unstructured":"Takura T, Nakanishi T, Kawanishi H, Nitta K, Akizawa T, Hiramatsu M, et al. Cost-effectiveness of maintenance hemodialysis in Japan. Ther Apher Dial. 2015;19:441\u20139.","journal-title":"Ther Apher Dial"},{"key":"2831_CR4","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s10157-019-01786-7","volume":"23","author":"A Fukui","year":"2019","unstructured":"Fukui A, Yokoo T, Nangaku M, Kashihara N. New measures against chronic kidney diseases in Japan since 2018. Clin Exp Nephrol. 2019;23:1263\u201371.","journal-title":"Clin Exp Nephrol"},{"key":"2831_CR5","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s10157-024-02537-z","volume":"28","author":"K Kanasaki","year":"2024","unstructured":"Kanasaki K, Ueki K, Nangaku M. Diabetic kidney disease: the kidney disease relevant to individuals with diabetes. Clin Exp Nephrol. 2024;28:1213\u201320.","journal-title":"Clin Exp Nephrol"},{"key":"2831_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/nep.14134","volume":"28","author":"M Wakasugi","year":"2023","unstructured":"Wakasugi M, Narita I. Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006-2020. Nephrol Carlton. 2023;28:119\u201329.","journal-title":"Nephrol Carlton"},{"key":"2831_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-019-0248-1","volume":"5","author":"K Nitta","year":"2019","unstructured":"Nitta K, Masakane I, Hanafusa N, Taniguchi M, Hasegawa T, Nakai S, et al. Annual dialysis data report 2017, JSDT renal data registry. Renal Replace Ther. 2019;5:53.","journal-title":"Renal Replace Ther"},{"key":"2831_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/jch.14736","volume":"25","author":"H Sakuma","year":"2023","unstructured":"Sakuma H, Matsuki M, Hasebe N, Nakagawa N. Real-world trends in pre-dialysis blood pressure levels of patients undergoing dialysis in Japan using a web-based national database. J Clin Hypertens (Greenwich). 2023;25:1163\u201371.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2831_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41440-023-01415-7","volume":"47","author":"H Sakuma","year":"2024","unstructured":"Sakuma H, Ikeda M, Nakao S, Suetsugu R, Matsuki M, Hasebe N, et al. Regional variation in pre-dialysis blood pressure and its association with cardiovascular mortality rates in Japanese patients undergoing dialysis. Hypertens Res. 2024;47:102\u201311.","journal-title":"Hypertens Res"},{"key":"2831_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41581-024-00868-4","volume":"20","author":"T Yamamoto","year":"2024","unstructured":"Yamamoto T, Isaka Y. Pathological mechanisms of kidney disease in ageing. Nat Rev Nephrol. 2024;20:603\u201315.","journal-title":"Nat Rev Nephrol"},{"key":"2831_CR11","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41581-024-00854-w","volume":"20","author":"S Kishi","year":"2024","unstructured":"Kishi S, Kadoya H, Kashihara N. Treatment of chronic kidney disease in older populations. Nat Rev Nephrol. 2024;20:586\u2013602.","journal-title":"Nat Rev Nephrol"},{"key":"2831_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","volume":"47","author":"PK-T Li","year":"2006","unstructured":"Li PK-T, Leung CB, Chow KM, Cheng YL, Fung SK-S, Mak SK, et al. Hong Kong study using Valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751\u201360.","journal-title":"Am J Kidney Dis"},{"key":"2831_CR13","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2006040347","volume":"18","author":"R Coppo","year":"2007","unstructured":"Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18:1880\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"2831_CR14","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","volume":"14","author":"M Praga","year":"2003","unstructured":"Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578\u201383.","journal-title":"J Am Soc Nephrol"},{"key":"2831_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s13300-020-00953-4","volume":"12","author":"M Durkin","year":"2021","unstructured":"Durkin M, Blais J. Linear projection of estimated glomerular filtration rate decline with Canagliflozin and implications for dialysis utilization and cost in diabetic nephropathy. Diabetes Ther. 2021;12:499\u2013508.","journal-title":"Diabetes Ther"},{"key":"2831_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100:215\u201324.","journal-title":"Kidney Int"},{"key":"2831_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","volume":"12","author":"Group E-KC","year":"2024","unstructured":"Group E-KC. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12:51\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2831_CR18","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1007\/s12325-024-02957-z","volume":"41","author":"P Kushner","year":"2024","unstructured":"Kushner P, Khunti K, Cebrian A, Deed G. Early identification and management of chronic kidney disease: a narrative review of the crucial role of primary care practitioners. Adv Ther. 2024;41:3757\u201370.","journal-title":"Adv Ther"},{"key":"2831_CR19","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s10157-024-02529-z","volume":"28","author":"Y Sota","year":"2024","unstructured":"Sota Y, Fujimaru T, Kobayashi K, Urayama KY, Kadota N, Konishi K, et al. Barriers to conservative kidney management for Japanese healthcare professionals involved in the treatment of end-stage renal disease. Clin Exp Nephrol. 2024;28:1261\u201371.","journal-title":"Clin Exp Nephrol"},{"key":"2831_CR20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/1744-9987.13705","volume":"26","author":"Y Maruyama","year":"2021","unstructured":"Maruyama Y, Niikura T, Nakashima A, Yamamoto H, Yokoo T. Long\u2010term changes in anemia\u2010related parameters among Japanese dialyzed patients assessed by newly developed web\u2010based system. Ther Apher Dial. 2021;26:362\u20137.","journal-title":"Ther Apher Dial"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02831-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02831-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02831-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T09:28:21Z","timestamp":1774258101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02831-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2831"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02831-y","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"9 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This retrospective study was conducted in accordance with the tenets of the Declaration of Helsinki and used existing national data without individual patient information; therefore, institutional review board approval and informed consent were not required, as previously reported [\n                      \n                      ,\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}]}}